Xanomeline

Xanomeline Impurities

Xanomeline impurities include synthetic intermediates, process-related compounds, degradation products, and residual solvents that may arise during synthesis, formulation, or storage. As a muscarinic acetylcholine receptor agonist under investigation for the treatment of neuropsychiatric disorders such as schizophrenia and Alzheimer’s disease, impurity profiling is essential to ensure product safety, therapeutic efficacy, and regulatory compliance. Known degradation pathways include hydrolysis and oxidative transformation of the amide and ether functionalities. All impurity compounds are structurally characterized and qualified under ICH guidelines for toxicological evaluation and analytical validation.

Xanomeline EP Impurities

Pharmacopeial and non-pharmacopeial Xanomeline impurity compounds are available in compliance with European Pharmacopoeia (EP) specifications. These standards support analytical method development, impurity profiling, and stability testing. EP traceable materials are supplied with validated analytical data including purity, structural confirmation, and spectral characterization.

Xanomeline Related Compounds

Structurally related compounds and synthetic analogs associated with Xanomeline are included for use in impurity identification, toxicological qualification, and regulatory submission. These materials are thoroughly characterized and conform to international standards. Related compounds are used in forced degradation studies, genotoxicity assessments, and impurity threshold evaluations.

Xanomeline Impurity Reference Standards

Xanomeline impurity reference standards are provided with validated analytical data including purity, NMR, MS, and full Certificates of Analysis. These standards are used in pharmaceutical research, method validation, and GMP-compliant quality control. EP/USP traceable entries are available upon request and are routinely re-tested to ensure consistency and reliability.